We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Logo

Evotec

Evotec are a R&D biotech that offers accelerating, high value pipeline co-creation partnerships and comprehensive CRO/CDMO services – always striving for highest quality, capital efficient execution of R&D programs from disease understanding towards IND, Phase 1, and beyond. Our expertise spans across therapeutic/disease areas and most modalities, especially small molecules and biotherapeutics. We take pride in acting as "drug hunters" in deep collaboration with our partners to advance science. At the core of our operations are our industrialized, AI-powered proprietary R&D platforms, including PanOmics and iPSC technologies. These platforms are instrumental in enhancing disease understanding and ensuring human relevance in our research. By integrating AI and continuous manufacturing technology, we facilitate better access to high-quality biotherapeutics, revolutionizing the way treatments are developed and produced.

Latest Evotec Content

A 3D model of a human brain with coloured string emitting from the sides.
Product News

Evotec Announces Progress in Strategic Neuroscience Partnership With Bristol Myers Squibb

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research.
A single floating cell on a blue background.
Article

The Omics Revolution: Multiomics and the Future of Biomedical Research

Combining different types of omics data offers tantalizing opportunities to gain a more comprehensive overview of cellular systems. This article will explore some of the latest advances in multiomics analysis that have opened up new frontiers in cell biology.
A machine with multiple tubes for mass spectrometry proteomics in Drug Discovery
Product
Advertisement

Evotec’s ScreenPep™ : the new benchmark in high-throughput proteomics

Our ScreenPep™ platform sets a new benchmark in high-throughput proteomics, enabling the analysis of thousands of samples at unparalleled speed and depth. Combining high-end mass spectrometry with automated sample preparation to achieve exceptional coverage and precision.
3d illustration of proteins
Whitepaper

Mass Spectrometry-Based Solutions for Drugging the Undruggable

This whitepaper highlights new drug discovery platforms that can uncover and pharmacologically target previously undruggable proteins targets, making them accessible to therapeutic intervention by small-molecule drugs.
Antibodies.
Product News

Just – Evotec Biologics Selected by U.S. Department of Defense for Manufacturing Optimization Program

Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s Manufacturing Optimization Program.
Advances in Drug Discovery & Development 2024
Online Event

Advances in Drug Discovery & Development 2024

On-Demand
This online event is aimed at those working within academia and pharmaceutical drug development, who want to hear from experts across their field. Focus will be given to the latest advances in small molecule drug discovery and development.
A purple brain.
Product News

Evotec Announces Progress in Neuroscience Collaboration With Bristol Myers Squibb

Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research.
Double helix structure of DNA.
Product News

Evotec and QIAGEN Enter Software Collaboration for Enhanced Multi-Omics Data Insights

Collaboration leverages synergies of QIAGEN’s OmicSoft omics data through Evotec’s analysis platform PanHunter.
A scientist holding a vial.
Product News

Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases

Partnership will expand Evotec’s molecular patient database in the area of metabolic diseases and in particular obesity.
Evotec receives € 7.5 m grant for development of COVID-19 therapeutic content piece image
Product News

Evotec receives € 7.5 m grant for development of COVID-19 therapeutic

Evotec SE has announced that the Company has been selected by the German Federal Ministry of Education and Research to receive a grant for the development of a potential first-in-class immunomodulatory therapy against COVID 19.
Advertisement